Skip directly to content

Matt Bomer and Simon Halls are longtime supporters of and have served on the boards for several not-for-profit organizations including GLSEN, AIDS Project Los Angeles, Family Equality Council, American Fertility Association, Project Angel Food, Project ALS, and Naked Angels Theater Company.

Bomer currently stars on the hit series American Horror Story opposite Lady Gaga and Kathy Bates. He was nominated for an Emmy Award and won a Golden Globe Award for his portrayal of Felix Turner in the Emmy Award–winning HBO film The Normal Heart. He

October 28, 2015

"In 1993, the World Health Organization declared TB a global emergency. The new data in the WHO's 2015 Global Tuberculosis Report show that all the promises made to end the TB epidemic since 1993 have been hollow. In 2014, 9.6 million people fell ill with TB, and 1.5 million died of it, making TB the world’s leading infectious killer—surpassing HIV. We have made no progress in reducing the incidence of multidrug-resistant TB (MDR-TB), with nearly half a million people developing MDR-TB in 2014, only one-fourth of them detected, and even fewer started on treatment.

We’re in

TAGline Fall 2015

By Tim Horn

In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.

TAGline Fall 2015

Federal legislation promises a substantial increase in NIH funding—at the expense of a significantly weakened FDA

By Kenyon Farrow

For more than a year, Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) of the House Energy and Commerce Committee hosted congressional hearings and nationwide town hall meetings to gather momentum for a bill they introduced in early 2015. Often bringing in people (including children) to give testimony about their particular disease or illness and the lack of available treatment or cure options, they spoke of a need to dramatically

TAGline Fall 2015

Can regulatory incentives promote responsible TB drug development?

By Lindsay McKenna and Erica Lessem

There are woefully few drugs in development with the potential to improve the safety and effectiveness of tuberculosis (TB) treatment. Indeed, the market-driven approach to drug development leaves most diseases not affecting wealthy countries without viable treatments and cures. To stimulate drug development for these conditions, the U.S.

TAGline Fall 2015

Supportive regulatory guidance for cure research requires a clear understanding of all possible outcomes, including remission

By Richard Jefferys

The term remission is increasingly being invoked in the context of cure research and, by extension, is an issue for regulatory authorities such as the U.S. Food and Drug Administration considering measurements of safety and efficacy in clinical trials.

TAGline Fall 2015

Worldwide inefficiencies in drug approval processes are proving disastrous for people living with TB and other diseases

By Erica Lessem

Access to safe and effective tuberculosis (TB) medicines depends greatly on efficient and stringent regulatory review, without which improved health outcomes are delayed. When it comes to evaluating new medicines, regulatory authorities have to balance multiple interests.

TAGline Fall 2015

Regulatory filing and review delays keep Truvada as pre-exposure prophylaxis out of reach of those who need it most

By Scott Morgan

Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent HIV acquisition. The U.S. Food and Drug Administration has approved only one medication as PrEP, in July 2012: a co-formulation, of tenofovir disoproxil fumarate (TDF) with emtricitabine (FTC), manufactured by Gilead. While early uptake in the United States was decidedly slow, education and promotion have increased demand in some vulnerable communities.

TAGline Fall 2015

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

October 2015

In Defense of Stringency
By Tim Horn

In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

TAGline Fall 2015: In Defense of Stringency

In Defense of Stringency
By Tim Horn

In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.

Pages